Filtered By:
Condition: Atrial Fibrillation
Management: Health Insurance
This page shows you your search results in order of relevance. This is page number 16.
Order by Relevance | Date
Total 264 results found since Jan 2013.
Statins reduce new-onset atrial fibrillation after acute myocardial infarction: A nationwide study
The objective of this study was to investigate whether statins confer a beneficial effect on AF after AMI.
Data available in the Taiwan National Health Insurance Research Database on 32886 AMI patients between 2008 and 2011 were retrospectively analyzed. Total 27553 (83.8%) had complete 1-yr follow-up data. Cardiovascular outcomes were analyzed based on the baseline characteristics and AF type (existing, new-onset, or non-AF). AF groups had significantly higher incidence of heart failure (HF), stroke, all-cause death, and major adverse cardiac and cerebrovascular event (MACCE) after index AMI (all P
Source: Medicine - January 1, 2020 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
Association Between Atrial Fibrillation and the Risk of Dementia in the Korean Elderly: A 10-Year Nationwide Cohort Study.
CONCLUSIONS: Investigating the potential risk factors of dementia in an aged society is important. We found a slightly higher risk of dementia in those with AF than in those without AF, and we therefore concluded that AF is a potential risk factor for dementia.
PMID: 32023675 [PubMed - in process]
Source: Journal of Preventive Medicine and Public Health - February 7, 2020 Category: International Medicine & Public Health Tags: J Prev Med Public Health Source Type: research
Pattern and Impact of Off-label Underdosing of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation Who Are Indicated for Standard Dosing
With safety concerns about increasing bleeding, off-label underdosing of non-vitamin K antagonist anticoagulants (NOACs) is common in East Asian patients with atrial fibrillation (AF). We tried to investigate the pattern of NOAC underdosing and associated clinical outcomes in patients with AF who are indicated for standard dosing. Using the Korean National Health Insurance Service database, we evaluated 16568 patients with a new prescription of NOAC who are indicated for standard NOAC dosing and compared 4536 patients with warfarin with respect to thromboembolic events (ischemic stroke or systemic embolization), all-cause ...
Source: The American Journal of Cardiology - February 6, 2020 Category: Cardiology Authors: Min Soo Cho, Ji Eun Yun, Ji Jeong Park, Yun Jung Kim, Jessie Lee, Hyungmin Kim, Duk-Woo Park, Gi-Byoung Nam Source Type: research
Oral Anticoagulants and Antiplatelet Agents in Atrial Fibrillation Patients with Concomitant Critical Limb Ischemia: A nationwide cohort study
ConclusionsDOAC was associated with a significantly lower risk of composite net-clinical-benefit outcome than either warfarin or APT in AF patients with concomitant CLI. Further prospective study is necessary to validate the findings in the future.
Source: Canadian Journal of Cardiology - February 19, 2020 Category: Cardiology Source Type: research
Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation.
CONCLUSIONS: Introduction of NOACs in routine practice for stroke prevention in AF was associated with improved rates of overall OAC use. However, significant practice-level variations in OAC and NOAC use remain producing social inequalities of OAC despite full reimbursement.
PMID: 32100483 [PubMed]
Source: Korean Circulation Journal - February 27, 2020 Category: Cardiology Tags: Korean Circ J Source Type: research
Or ális antikoagulánssal kezelt pitvarfibrilláló betegek terápiahűsége a mindennapokban.
Conclusions: The one-year persistence of NOACs was significantly higher in AF compared to VKA therapy (in therapy-naïve and in already treated patients, too). Among the NOACs, rivaroxaban has the best one-year persistence in all patient populations. Orv Hetil. 2020; 161(20): 839-845.
PMID: 32364687 [PubMed - in process]
Source: Orvosi Hetilap - April 30, 2020 Category: General Medicine Authors: Simonyi G, Paksy A, Várnai R, Medvegy M Tags: Orv Hetil Source Type: research
Novel Oral Anticoagulant versus Warfarin in Cancer Patients with Atrial Fibrillation: An 8-Year Population-Based Cohort Study
Conclusion: In cancer patients with AF, NOAC were associated with significant reduced IS/SE, major bleeding, and ICH compared to warfarin.
Source: Journal of Cancer - July 2, 2020 Category: Cancer & Oncology Authors: Victor Chien-Chia Wu, Chun-Li Wang, Yu-Tung Huang, Wen-Ching Lan, Michael Wu, Chang-Fu Kuo, Shao-Wei Chen, Pao-Hsien Chu, Ming-Shien Wen, Chi-Ching Kuo, Shang-Hung Chang Tags: Research Paper Source Type: research
Concomitant Use of NSAIDs or SSRIs with NOACs Requires Monitoring for Bleeding.
CONCLUSION: When NSAIDs or SSRIs are required for NOAC users with AF, physicians need to monitor bleeding events and consider the use of PPIs, especially for combined use of both drugs or when initiating NOACs treatment.
PMID: 32882758 [PubMed - in process]
Source: Yonsei Medical Journal - August 31, 2020 Category: Universities & Medical Training Authors: Lee MT, Park KY, Kim MS, You SH, Kang YJ, Jung SY Tags: Yonsei Med J Source Type: research
Effectiveness and Safety of Direct Oral Anticoagulants in an Asian Population with Atrial Fibrillation Undergoing Dialysis: A Population-Based Cohort Study and Meta-Analysis
ConclusionsDOACs did not provide benefit over warfarin regarding effectiveness and safety in AF patients undergoing dialysis. The use of OAC was not associated with a lower risk of IS/SE in ESRD AF patients when compared to those without OAC use.
Source: Cardiovascular Drugs and Therapy - November 19, 2020 Category: Cardiology Source Type: research
Thromboembolic events in atrial fibrillation: Different level of risk and pattern between peripheral artery disease and coronary artery disease.
CONCLUSIONS: PAD or CAD in patients with AF did not contribute equally to the risk prediction and presentation of IS and STE. Patients with polyvascular disease should be considered at higher risk than those with either condition.
PMID: 33518472 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - January 28, 2021 Category: Cardiology Authors: Lin YS, Wu VC, Chen YL, Liu CH, Chen HC, Lee WC, Yang TY, Aboyans V, Chen MC Tags: Arch Cardiovasc Dis Source Type: research
Association of anticoagulant therapy with risk of dementia among patients with atrial fibrillation
ConclusionIn this propensity-matched and -weighted analysis using a real-world population-based cohort, use of NOACs was associated with lower dementia risk than use of warfarin among non-valvular AF patients initiating OAC treatment.
Source: Europace - October 16, 2020 Category: Cardiology Source Type: research
Frailty and the Effect of Catheter Ablation in the Elderly Population With Atrial Fibrillation - A Real-World Analysis
CONCLUSIONS: Ablation may be associated with a lower risk of death and composite outcome in non-frail elderly, but the beneficial effect of ablation was not significant in frail elderly patients with AF. The effect of frailty on the outcome of ablation should be evaluated in further studies.PMID:33731545 | DOI:10.1253/circj.CJ-20-1062
Source: Circulation Journal - March 18, 2021 Category: Cardiology Authors: Pil-Sung Yang Jung-Hoon Sung Daehoon Kim Eunsun Jang Hee Tae Yu Tae-Hoon Kim Jae-Sun Uhm Jong-Youn Kim Hui-Nam Pak Moon-Hyoung Lee Boyoung Joung Source Type: research
